Skip to main content
Business

Novo Nordisk eats Eli Lilly’s dust again

The airball comes as Novo scrambles to regain a majority share of the GLP-1 market.

• less than 3 min read

TOPICS: Business / Industries / Healthcare

The maker of Ozempic and Wegovy keeps slipping on banana peels when it tries to regain its position in GLP-1s. Yesterday, Novo Nordisk announced that a new weight loss shot it hoped would rival Eli Lilly’s injectable actually underperformed in a head-to-head trial, tanking Novo’s stock.

Shares of the Danish drugmaker fell 16% on the news that Novo’s CagriSema delivered 20.2% weight loss in 84 weeks, compared with 23.6% for Lilly’s tirzepatide, aka Zepbound. The airball comes as Novo scrambles to regain a majority share of the GLP-1 market, which it lost to Lilly in recent months.

“This outcome is the worst-case scenario,” said Michael Shah, a Bloomberg Intelligence analyst. The disappointment follows a management shakeup, a failed semaglutide Alzheimer’s trial, and a failed acquisition of a promising biotech company. Novo’s GLP-1 patents are also set to expire sooner than Lilly’s, which is another reason it was counting on CagriSema to succeed.

To make matters worse for Novo, Lilly’s stock climbed a few points yesterday after it launched a new version of its Zepbound injectable, which holds a month’s worth of shots—up from one week for its current devices.

How the mighty have fallen: Novo has lost ~$475 billion in value since 2024, when it was worth $650+ billion. Its stock price now verges on pre-Wegovy times.

Become smarter in just 5 minutes

Morning Brew delivers quick and insightful updates about the business world every day of the week from Wall St. to Silicon Valley.

By subscribing, you accept our Terms & Privacy Policy.

About the author

Molly Liebergall

Morning Brew

Morning Brew delivers quick and insightful updates about the business world every day of the week from Wall St. to Silicon Valley.

By subscribing, you accept our Terms & Privacy Policy.